Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Unperturbed expression bias of imprinted genes in schizophrenia.

Gulyás-Kovács A, Keydar I, Xia E, Fromer M, Hoffman G, Ruderfer D, Sachidanandam R, Chess A.

Nat Commun. 2018 Jul 25;9(1):2914. doi: 10.1038/s41467-018-04960-9.

2.

The importance of DNA methylation of exons on alternative splicing.

Shayevitch R, Askayo D, Keydar I, Ast G.

RNA. 2018 Oct;24(10):1351-1362. doi: 10.1261/rna.064865.117. Epub 2018 Jul 12.

3.

The human olfactory transcriptome.

Olender T, Keydar I, Pinto JM, Tatarskyy P, Alkelai A, Chien MS, Fishilevich S, Restrepo D, Matsunami H, Gilad Y, Lancet D.

BMC Genomics. 2016 Aug 11;17(1):619. doi: 10.1186/s12864-016-2960-3.

4.

General olfactory sensitivity database (GOSdb): candidate genes and their genomic variations.

Keydar I, Ben-Asher E, Feldmesser E, Nativ N, Oshimoto A, Restrepo D, Matsunami H, Chien MS, Pinto JM, Gilad Y, Olender T, Lancet D.

Hum Mutat. 2013 Jan;34(1):32-41. doi: 10.1002/humu.22212. Epub 2012 Oct 11.

5.

Systematic inference of copy-number genotypes from personal genome sequencing data reveals extensive olfactory receptor gene content diversity.

Waszak SM, Hasin Y, Zichner T, Olender T, Keydar I, Khen M, Stütz AM, Schlattl A, Lancet D, Korbel JO.

PLoS Comput Biol. 2010 Nov 11;6(11):e1000988. doi: 10.1371/journal.pcbi.1000988.

6.

Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions.

Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Ryvo L, Cohen-Hillel E, Shtabsky A, Ehrlich M, Meshel T, Keydar I, Ben-Baruch A.

Cytokine. 2008 Oct;44(1):191-200. doi: 10.1016/j.cyto.2008.08.002. Epub 2008 Sep 13.

PMID:
18790652
7.

Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker.

Golan M, Hizi A, Resau JH, Yaal-Hahoshen N, Reichman H, Keydar I, Tsarfaty I.

Neoplasia. 2008 Jun;10(6):521-33.

8.

Antibody internalization studied using a novel IgG binding toxin fusion.

Mazor Y, Barnea I, Keydar I, Benhar I.

J Immunol Methods. 2007 Apr 10;321(1-2):41-59. Epub 2007 Feb 6.

PMID:
17336321
10.

The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients.

Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, Azenshtein E, Greenberg I, Keydar I, Ben-Baruch A.

Clin Cancer Res. 2006 Aug 1;12(15):4474-80. Review.

11.

A novel protein derived from the MUC1 gene by alternative splicing and frameshifting.

Levitin F, Baruch A, Weiss M, Stiegman K, Hartmann ML, Yoeli-Lerner M, Ziv R, Zrihan-Licht S, Shina S, Gat A, Lifschitz B, Simha M, Stadler Y, Cholostoy A, Gil B, Greaves D, Keydar I, Zaretsky J, Smorodinsky N, Wreschner DH.

J Biol Chem. 2005 Mar 18;280(11):10655-63. Epub 2004 Dec 28.

12.

The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors.

Azenshtein E, Meshel T, Shina S, Barak N, Keydar I, Ben-Baruch A.

Cancer Lett. 2005 Jan 10;217(1):73-86.

PMID:
15596298
13.

A unique mucin immunoenhancing peptide with antitumor properties.

Herbert LM, Grosso JF, Dorsey M Jr, Fu T, Keydar I, Cejas MA, Wreschner DH, Smorodinski N, Lopez DM.

Cancer Res. 2004 Nov 1;64(21):8077-84.

14.
15.

Breast carcinoma: a report on the potential usage of the CC chemokine RANTES as a marker for a progressive disease.

Wigler N, Shina S, Kaplan O, Luboshits G, Chaitchik S, Keydar I, Ben-Baruch A.

Isr Med Assoc J. 2002 Nov;4(11 Suppl):940-3.

PMID:
12455185
16.

The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity.

Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, Wigler N, Keydar I, Ben-Baruch A.

Cancer Res. 2002 Feb 15;62(4):1093-102.

17.

Generation of ligand-receptor alliances by "SEA" module-mediated cleavage of membrane-associated mucin proteins.

Wreschner DH, McGuckin MA, Williams SJ, Baruch A, Yoeli M, Ziv R, Okun L, Zaretsky J, Smorodinsky N, Keydar I, Neophytou P, Stacey M, Lin HH, Gordon S.

Protein Sci. 2002 Mar;11(3):698-706.

18.

Functional analysis of Csk and CHK kinases in breast cancer cells.

Bougeret C, Jiang S, Keydar I, Avraham H.

J Biol Chem. 2001 Sep 7;276(36):33711-20. Epub 2001 Jul 9.

19.

RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion.

Zrihan-Licht S, Fu Y, Settleman J, Schinkmann K, Shaw L, Keydar I, Avraham S, Avraham H.

Oncogene. 2000 Mar 2;19(10):1318-28.

20.

Analysis of the promoter of the MUC1 gene overexpressed in breast cancer.

Zaretsky JZ, Sarid R, Aylon Y, Mittelman LA, Wreschner DH, Keydar I.

FEBS Lett. 1999 Nov 19;461(3):189-95.

21.

Alteration of Met protooncogene product expression and prognosis in breast carcinomas.

Tsarfaty I, Alvord WG, Resau JH, Altstock RT, Lidereau R, Bieche I, Bertrand F, Horev J, Klabansky RL, Keydar I, Vande Woude GF.

Anal Quant Cytol Histol. 1999 Oct;21(5):397-408.

PMID:
10560522
22.

Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma.

Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I, Ben-Baruch A.

Cancer Res. 1999 Sep 15;59(18):4681-7.

23.

MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer.

Hartman M, Baruch A, Ron I, Aderet Y, Yoeli M, Sagi-Assif O, Greenstein S, Stadler Y, Weiss M, Harness E, Yaakubovits M, Keydar I, Smorodinsky NI, Wreschner DH.

Int J Cancer. 1999 Jul 19;82(2):256-67.

24.

The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein.

Baruch A, Hartmann M, Yoeli M, Adereth Y, Greenstein S, Stadler Y, Skornik Y, Zaretsky J, Smorodinsky NI, Keydar I, Wreschner DH.

Cancer Res. 1999 Apr 1;59(7):1552-61.

25.
26.

Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function.

Baruch A, Hartmann M, Zrihan-Licht S, Greenstein S, Burstein M, Keydar I, Weiss M, Smorodinsky N, Wreschner DH.

Int J Cancer. 1997 May 29;71(5):741-9.

27.

Humanization of an antibody recognizing a breast cancer specific epitope by CDR-grafting.

Fiorentini S, Matczak E, Gallo RC, Reitz MS, Keydar I, Watkins BA.

Immunotechnology. 1997 Mar;3(1):45-59.

PMID:
9154467
28.

Association of csk-homologous kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in breast cancer cells.

Zrihan-Licht S, Lim J, Keydar I, Sliwkowski MX, Groopman JE, Avraham H.

J Biol Chem. 1997 Jan 17;272(3):1856-63.

29.

Detection of a secreted MUC1/SEC protein by MUC1 isoform specific monoclonal antibodies.

Smorodinsky N, Weiss M, Hartmann ML, Baruch A, Harness E, Yaakobovitz M, Keydar I, Wreschner DH.

Biochem Biophys Res Commun. 1996 Nov 1;228(1):115-21.

PMID:
8912645
30.
31.

DNA methylation status of the MUC1 gene coding for a breast-cancer-associated protein.

Zrihan-Licht S, Weiss M, Keydar I, Wreschner DH.

Int J Cancer. 1995 Jul 28;62(3):245-51.

PMID:
7628867
32.

Detection of retroviral superantigen and products of the envelope gene from endogenous mouse mammary tumor virus in B cells from BALB/c mice.

Lopez-Cepero M, Wang Y, Keydar I, Brandt-Carlson C, Butel JS, Lopez DM.

Cell Immunol. 1995 Jul;163(2):191-7.

PMID:
7606792
33.

Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules.

Zrihan-Licht S, Baruch A, Elroy-Stein O, Keydar I, Wreschner DH.

FEBS Lett. 1994 Dec 12;356(1):130-6.

34.

Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue.

Zrihan-Licht S, Vos HL, Baruch A, Elroy-Stein O, Sagiv D, Keydar I, Hilkens J, Wreschner DH.

Eur J Biochem. 1994 Sep 1;224(2):787-95.

35.

Does a novel form of the breast cancer marker protein, MUC1, act as a receptor molecule that modulates signal transduction?

Wreschner DH, Zrihan-Licht S, Baruch A, Sagiv D, Hartman ML, Smorodinsky N, Keydar I.

Adv Exp Med Biol. 1994;353:17-26.

PMID:
7985536
36.

Vaccination against breast cancer--studies in an animal model.

Smorodinsky NI, Yarden R, Carmon L, Hareuveni M, Wreschner DH, Keydar I.

Adv Exp Med Biol. 1994;353:125-37. No abstract available.

PMID:
7985531
37.

The met proto-oncogene receptor and lumen formation.

Tsarfaty I, Resau JH, Rulong S, Keydar I, Faletto DL, Vande Woude GF.

Science. 1992 Aug 28;257(5074):1258-61.

PMID:
1387731
38.

Recognition of peptidyl epitopes by polymorphic epithelial mucin (PEM)-specific monoclonal antibodies.

Dion AS, Smorodinsky NI, Williams CJ, Wreschner DH, Major PP, Keydar I.

Hybridoma. 1991 Oct;10(5):595-610.

PMID:
1804772
39.

Vaccinia recombinants expressing secreted and transmembrane forms of breast cancer-associated epithelial tumour antigen (ETA).

Hareuveni M, Wreschner DH, Kieny MP, Dott K, Gautier C, Tomasetto C, Keydar I, Chambon P, Lathe R.

Vaccine. 1991 Sep;9(9):618-26.

PMID:
1950095
40.

Expression of a gene coding for breast tumor-associated antigen in thyroid papillary carcinoma.

Weiss M, Zaretsky J, Zimlichman R, Smorodinsky N, Dion AS, Keydar I, Wreschner DH.

Cancer Lett. 1991 Jun 14;58(1-2):125-30.

PMID:
2049778
41.

The production of human monoclonal anti-MMTV antibodies by in vitro immunization with anti-idiotypic antibodies.

Blank M, Smorodinsky IN, Keydar I, Chaitchik S, Shoenfeld Y.

Immunol Lett. 1991 Apr;28(1):65-71.

PMID:
1649130
42.

Isolation and characterization of an expressed hypervariable gene coding for a breast-cancer-associated antigen.

Tsarfaty I, Hareuveni M, Horev J, Zaretsky J, Weiss M, Jeltsch JM, Garnier JM, Lathe R, Keydar I, Wreschner DH.

Gene. 1990 Sep 14;93(2):313-8.

PMID:
1688329
43.

Multiple protein forms of the human breast tumor-associated epithelial membrane antigen (EMA) are generated by alternative splicing and induced by hormonal stimulation.

Williams CJ, Wreschner DH, Tanaka A, Tsarfaty I, Keydar I, Dion AS.

Biochem Biophys Res Commun. 1990 Aug 16;170(3):1331-8.

PMID:
2202302
44.

Expression of genes coding for pS2, c-erbB2, estrogen receptor and the H23 breast tumor-associated antigen. A comparative analysis in breast cancer.

Zaretsky JZ, Weiss M, Tsarfaty I, Hareuveni M, Wreschner DH, Keydar I.

FEBS Lett. 1990 Jun 4;265(1-2):46-50.

45.

A transcribed gene, containing a variable number of tandem repeats, codes for a human epithelial tumor antigen. cDNA cloning, expression of the transfected gene and over-expression in breast cancer tissue.

Hareuveni M, Tsarfaty I, Zaretsky J, Kotkes P, Horev J, Zrihan S, Weiss M, Green S, Lathe R, Keydar I, et al.

Eur J Biochem. 1990 May 20;189(3):475-86.

46.

Production and characterization of monoclonal antibodies identifying breast tumor-associated antigens.

Keydar I, Chou CS, Hareuveni M, Tsarfaty I, Sahar E, Selzer G, Chaitchik S, Hizi A.

Proc Natl Acad Sci U S A. 1989 Feb;86(4):1362-6.

47.

Towards an idiotype vaccine against mammary tumors. Induction of an immune response to breast cancer-associated antigens by anti-idiotypic antibodies.

Smorodinsky NI, Ghendler Y, Bakimer R, Chaitchuk S, Keydar I, Shoenfeld Y.

Eur J Immunol. 1988 Nov;18(11):1713-8.

PMID:
2849550
48.

Prognostic factors in breast cancer--a pathological and immunological study of patients with stage 1 breast cancer.

Chaitchik S, Kabakow B, De Chabon A, Jonson JJ, Bar-Eyal A, Selzer G, Feuer EJ, Keydar I, Hizi A.

Eur J Surg Oncol. 1987 Dec;13(6):499-504.

PMID:
2826257
49.
50.

Supplemental Content

Loading ...
Support Center